Eloxx Pharmaceuticals Executes 1-for-11 Reverse Stock Split and Appoints New Directors

summarizeSummary

Eloxx Pharmaceuticals executed a 1-for-11 reverse stock split and reduced its authorized shares, effective May 29, 2026, with split-adjusted trading beginning today. The company also appointed two new independent directors to its board.

check_boxKey Events

• 1-for-11 Reverse Stock Split Executed

  The Board approved and executed a 1-for-11 reverse stock split, effective May 29, 2026. Common Stock is expected to begin trading on a split-adjusted basis on the OTC Pink Market today, June 1, 2026. This follows prior stockholder approvals.

• Authorized Shares Reduced

  The number of authorized common shares was decreased from 500,000,000 to 100,000,000, effective May 29, 2026, in conjunction with the reverse stock split.

• New Independent Directors Appointed

  Stephen W. Webster (a financial expert) and Nina Kjellson were appointed to the Board of Directors on May 27, 2026. The Board size was simultaneously reduced from six to five directors.

• Director Equity Awards Granted

  Each new director received an option grant to purchase 13,587 shares of Common Stock, with an exercise price per share equal to the public offering price of a pending registration statement.

auto_awesomeAnalysis

The execution of a 1-for-11 reverse stock split is a critical event for this micro-cap company, often a measure taken to meet minimum price requirements for exchange listing or to improve stock perception. While it consolidates shares and increases the per-share price, it does not change the company's underlying valuation or financial health. The reduction in authorized shares is a related corporate governance move. The appointment of two new independent directors, including a financial expert, is a positive for corporate governance, but the overall context of the reverse split and pending dilutive offering (as per prior S-1 filing) suggests ongoing financial challenges.